7284University of Washington, Seattle, WA, USA.
3989Baylor College of Medicine, Houston, TX, USA.
Biol Res Nurs. 2021 Jul;23(3):471-480. doi: 10.1177/1099800420984543. Epub 2021 Jan 8.
Changes in diet and lifestyle factors are frequently recommended for persons with irritable bowel syndrome (IBS). It is unknown whether these recommendations alter the gut microbiome and/or whether baseline microbiome predicts improvement in symptoms and quality of life following treatment. Therefore, the purpose of this study was to explore if baseline gut microbiome composition predicted response to a Comprehensive Self-Management (CSM) intervention and if the intervention resulted in a different gut microbiome composition compared to usual care.
Individuals aged 18-70 years with IBS symptoms ≥6 months were recruited using convenience sampling. Individuals were excluded if medication use or comorbidities would influence symptoms or microbiome. Participants completed a baseline assessment and were randomized into the eight-session CSM intervention which included dietary education and cognitive behavioral therapy versus usual care. Questionnaires included demographics, quality of life, and symptom diaries. Fecal samples were collected at baseline and 3-month post-randomization for 16S rRNA-based microbiome analysis.
Within the CSM intervention group (n = 30), Shannon diversity, richness, and beta diversity measures at baseline did not predict benefit from the CSM intervention at 3 months, as measured by change in abdominal pain and quality of life. Based on both alpha and beta diversity, the change from baseline to follow-up microbiome bacterial taxa did not differ between CSM (n = 25) and usual care (n = 25).
Baseline microbiome does not predict symptom improvement with CSM intervention. We do not find evidence that the CSM intervention influences gut microbiome diversity or composition over the course of 3 months.
饮食和生活方式因素的改变常被推荐用于肠易激综合征(IBS)患者。目前尚不清楚这些建议是否会改变肠道微生物群,以及基线微生物群是否可以预测治疗后症状和生活质量的改善。因此,本研究旨在探索基线肠道微生物群组成是否可以预测综合自我管理(CSM)干预的反应,以及干预是否会导致与常规护理相比肠道微生物群组成的不同。
采用便利抽样法招募年龄在 18-70 岁之间、IBS 症状≥6 个月的患者。如果药物使用或合并症会影响症状或微生物群,则将患者排除在外。参与者完成基线评估,并随机分为 8 节 CSM 干预组,包括饮食教育和认知行为疗法与常规护理。问卷包括人口统计学、生活质量和症状日记。在基线和随机分组后 3 个月收集粪便样本进行 16S rRNA 微生物组分析。
在 CSM 干预组(n=30)中,基线时 Shannon 多样性、丰富度和 beta 多样性测量值均不能预测 CSM 干预 3 个月时的获益,以腹痛和生活质量的变化来衡量。基于 alpha 和 beta 多样性,从基线到随访的微生物群细菌分类群的变化在 CSM(n=25)和常规护理(n=25)之间没有差异。
基线微生物群不能预测 CSM 干预的症状改善。我们没有发现证据表明 CSM 干预会在 3 个月的时间内影响肠道微生物群的多样性或组成。